← All trials
NCT06280196
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 19, 2024
- Primary completion
- Jul 30, 2027
- Completion date
- Oct 30, 2028
- First posted
- Feb 28, 2024
- Last posted
- Aug 30, 2024
- Enrollment
- 676
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BiotheraLead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.